Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan

American Journal of Hematology

Volumn 82, Issue 10, 2007, Pages 873-880

  Saito, Akiko M ^a,b,n   Kami, Masahiro ^b   Mori, Shin Ichiro ^c   Kanda, Yoshinobu ^d   Suzuki, Ritsuro ^e   Mineishi, Shin ^f   Takami, Akiyoshi ^g   Taniguchi, Shuichi ^h   Takemoto, Yoshinobu ⁱ   Hara, Masamichi ^j   Yamaguchi, Masaki ^k   Hino, Masayuki ^l   Yoshida, Takashi ^m   Kim, Sung Won ^c   Hori, Akiko ^c   Ohashi, Yasuo ^b   Takaue, Yoichi ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^e NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF MICHIGAN   (United States)

^g KANAZAWA UNIVERSITY   (Japan)

^h TORANOMON HOSPITAL   (Japan)

ⁱ Medical Corporation Kouryokai CPC Clinic   (Japan)

^j EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^k ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^l OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m TOYAMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

ⁿ DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD3 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; FLUDARABINE; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLADDER DISEASE; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HLA MATCHING; HUMAN; HUMAN CELL; LIVER TOXICITY; LUNG TOXICITY; MALE; MONOTHERAPY; MORTALITY; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; SAFETY; STOMATITIS; T LYMPHOCYTE;

ADULT; AGED; BUSULFAN; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFUSION; MALE; METHOTREXATE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 34848840898     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20977     Document Type: Article

References (41)

1. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005;105:1810-1814.
2. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003;21:1480-1484.
3. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-3400.
4. Shimoni A, Kroger N, Zabelina T, et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: Older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 2005;19:7-12.
5. Shapira MY, Resnick IB, Bitan M, et al. Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients. Bone Marrow Transplant 2004;34:155-159.
6. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-763.
7. Wong R, Giralt SA, Martin T, et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003;102:3052-3059.
8. Tsirigotis P, Bitan RO, Resnick IB, et al. A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients. Haematologica 2006;91:852-855.
9. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-4536.
10. Kroger N, Shimoni A, Zabelina T, et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 2006;37:339-344.
11. Gupta V, Daly A, Lipton JH, et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 2005;11:764-772.
12. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824.
13. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003;101:1620-1629.
14. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234-3241.
15. Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004;104:2254-2262.
16. Bornhauser M, Storer B, Slattery JT, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003;102:820-826.
17. Keil F, Prinz E, Moser K, et al. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival. Transplantation 2003;76:230-236.
18. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988;6:1562-1568.
19. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-828.
20. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217.
21. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 1998;20:543-549.
22. Bornhauser M, Thiede C, Schuler U, et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: Durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000;26:119-125.
23. Schetelig J, Bornhauser M, Kiehl M, et al. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation - A retrospective analysis. Bone Marrow Transplant 2004;33:483-490.
24. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003;102:2021-2030.
25. Hamaki T, Kami M, Kim SW, et al. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. Bone Marrow Transplant 2004;33:891-900.
26. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblasts leukaemia: A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for blood and marrow transplantation (EBMT). Leukemia 2005;19:2304-2312.
27. Schattenberg A, Schaap N, Preijers F, van der Maazen R, de Witte T. Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients. Bone Marrow Transplant 2000;26:17-22.
28. Du W, Dansey R, Abella EM, et al. Successful allogeneic bone marrow transplantation in selected patients over 50 years of age - A single institution's experience. Bone Marrow Transplant 1998;21:1043-1047.
29. Ringden O, Horowitz MM, Gale RR et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993;270:57-60.
30. Farag SS, Elder PJ, Marcucci G, et al. Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged ≥50 years compared to younger adults with low-risk disease. Bone Marrow Transplant 2003;31:87-93.
31. Taussig DC, Davies AJ, Cavenagh JD, et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol 2003;21:3060-3065.
32. Mineishi S, Kanda Y, Saito T, et al. Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. Br J Haematol 2003;121:296-303.
33. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-762.
34. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: A meta-analysis. J Clin Oncol 2001;19: 3685-3691.
35. Mielcarek M, Storb R. Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. Leuk Lymphoma 2005;46:1251-1260.
36. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992;80:1838-1845.
37. Weisdorf D, Hakke R, Blazar B, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991;51:1197-1203.
38. Burroughs L, Mielcarek M, Leisenring W, et al. Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Transplantation 2006;81:818-825.
39. Ochs LA, Miller WJ, Filipovich AH, et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transplant 1994;13:455-460.
40. Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003;102:470-476.
41. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002;99:1943-1951.